Lipid lowering therapy patterns in patients with ASCVD and familial hypercholesterolemia in Israel
Lipid lowering therapy patterns observed in Israeli patients
This retrospective database study examined lipid lowering therapy patterns among patients with atherosclerotic cardiovascular disease, ASCVD…
A look at how patients with high cholesterol and heart disease manage their lipid lowering therapy and treatment adherence in Israel.
Liver biomarkers improve ASCVD risk prediction in US and Chinese cohorts
Researchers find liver biomarkers linked to heart disease risk
This cohort study evaluated liver function biomarkers for 10-year hard ASCVD risk prediction in US and Chinese populations. GGT showed a pos…
A new study shows liver function markers may help predict heart disease risk beyond traditional factors, especially in US and Chinese adults…
Lipoprotein(a) concentrations associate with coronary artery disease severity in single-center observational cohort of 238 adults.
Higher Lipoprotein(a) Linked to Worse Heart Disease Severity
This single-center observational cohort study assessed Lipoprotein(a) concentrations in 238 adults referred for elective coronary angiograph…
Higher levels of lipoprotein(a) were found in patients with more severe coronary artery disease blockages in Kazakhstan.
Mendelian Randomization review links Lp(a) to inflammatory protein pathways
Lp(a) may influence heart disease through inflammation pathways
This Mendelian Randomization analysis identifies 521 proteins associated with Lp(a) and 91 downstream proteins in MACE-relevant pathways. Th…
Genetic analysis links Lp(a) to 521 proteins and inflammation pathways that could affect heart disease risk, offering a new mechanistic insi…
Review links periodontitis to higher cardiovascular risk but notes causal inference is unproven.
Does gum disease truly raise your risk for heart attacks and strokes?
This narrative review synthesizes evidence regarding the association between periodontitis and atherosclerotic cardiovascular disease, coron…
Severe gum disease is linked to a small increase in heart attack and stroke risk, but experts say we lack proof that treating your gums will…
Plasma proteomic profiles predict recurrent ASCVD events better than SMART2 risk scores in UK Biobank participants.
Blood Proteins Reveal Hidden Heart Risk After Disease Strikes
This cohort study of ~9,300 UK Biobank participants with established ASCVD compared plasma proteomic profiles against the SMART2 clinical ri…
Measuring specific proteins in blood could help doctors spot heart risks earlier than before.
CAC progression assessed in 467 IBD patients without known ASCVD
Routine Chest Scans May Reveal Hidden Heart Risk in IBD Patients
This multicenter retrospective cohort study evaluated 467 inflammatory bowel disease patients without known atherosclerotic cardiovascular d…
For people with IBD, watching how heart artery calcium changes over time could be the key to preventing a future heart attack.
Pitavastatin showed no difference in health-related quality of life compared with placebo in people with HIV.
Why Heart Risk Factors Drag Down Daily Wellbeing for People With HIV
This randomized controlled trial evaluated pitavastatin versus placebo in 733 people with HIV aged 40 to 75 years on antiretroviral therapy …
Common heart risks like smoking and high BMI hurt daily physical wellbeing for people with HIV, while statins showed no visible improvement …
Meta-analysis finds colchicine associated with reduced MACE in ASCVD, but heterogeneity is substantial
Colchicine linked to fewer heart events in people with existing heart disease
A systematic review and meta-analysis of 5 RCTs (n=18,656 adults with established ASCVD) found colchicine was associated with reduced 4-poin…
A cautious statistical review of five trials found no solid proof that low-dose colchicine reduces major heart events in adults with existin…
Meta-analysis: Colchicine reduces MACE by 17%, eMACE by 23% in ASCVD
Can an old anti-inflammatory drug help prevent heart attacks? A review of 11 trials suggests it might.
A meta-analysis of 11 trials (n=30,808) found low-dose colchicine was associated with a 17% reduction in MACE (RR 0.83, 95% CI 0.73-0.95; P=…
Adding a low-dose anti-inflammatory drug called colchicine to heart disease treatment lowers the risk of heart attacks and strokes by 17%.